Nusinersen (Spinraza®) is one of the innovative oligonucleotide-based therapies administered to patients with spinal muscular atrophy (SMA). The need to inject it intrathecally is sometimes technically difficult, especially in cases of spinal deformity. According to the multidisciplinary team at the Boston reference centre (USA), which treated 82 then 125 children with SMA in two phases, it appears that :
- the 1,415 cumulative injections were carried out without any particular incident in the vast majority of cases;
- of these, 137 were carried out via a reservoir and 55 via a formaminal route due to complex spinal anatomy;
- half of the injections are now performed by neurology nurse practitioners.